Every 8-K that Skye Bioscience (SKYE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SKYE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SKYE filings page.
Skye Bioscience, Inc. (SKYE) entered into a Securities Purchase Agreement with Redmile Biopharma Investments III, L.P. establishing an equity line of credit (the “ELOC”) for up to $22,000,000 of common and non-voting common shares. The ELOC size is reduced by equity proceeds from the PIPE above $103,000,000 and is eliminated if funded PIPE proceeds reach $125,000,000.
Skye must, after commencement, direct monthly purchases of up to $2,000,000 of ELOC shares for three years from the PIPE closing, at a price per share based on the lesser of the PIPE Price and Market Price, but not below a 10% discount to the PIPE Price. Skye will also issue Redmile a warrant sized at $5,000,000 divided by the PIPE Price, exercisable from January 1, 2027 to January 1, 2030, with a floor exercise price of 90% of the PIPE Price. Issuances are constrained by a 19.99% Nasdaq exchange cap and a 9.99% beneficial ownership limit, with excess issuances structured as non-voting common stock. Skye agreed to register resales of the ELOC and conversion shares within 10 business days of the PIPE closing.
Skye Bioscience, Inc. (SKYE) filed an amendment to update the effective timing of a previously approved reverse stock split. The company states that the related Certificate will become effective at 12:01 a.m. New York time on August 24, 2026, with its common stock beginning to trade on Nasdaq on a split-adjusted basis at that day’s market open. The common stock will continue to trade under the ticker “SKYE”, and the new CUSIP for the post–reverse split shares will be 83086J309. Skye also reiterates that it plans to file a proxy statement with the SEC in connection with its proposed acquisition of Redx Pharma Limited and provides standard cautionary language regarding forward-looking statements and the risks that could affect completion and integration of the transaction and Nasdaq listing compliance.
Skye Bioscience, Inc. (SKYE) reports that Nasdaq has notified the company it is not in compliance with Nasdaq Capital Market Listing Rule 5550(b)(1) because stockholders’ equity was ($497,307) as of June 30, 2026, below the required $2,500,000. The notice does not immediately affect trading and SKYE shares continue on the Nasdaq Capital Market. Skye has 45 days, until October 2, 2026, to submit a plan to regain compliance, after which Nasdaq may grant up to 180 days from the notice date, to February 14, 2027, to demonstrate compliance. Skye is evaluating alternatives and also continues to pursue its proposed acquisition of Redx Pharma Limited, which will be submitted to Skye stockholders via a proxy statement.
Skye Bioscience entered a definitive agreement to acquire Redx Pharma via a UK scheme of arrangement and combine as Fibrx Therapeutics, a fibrosis-focused biotech expected to trade on Nasdaq and be led by the current Redx management team and board.
Based on the agreed Exchange Ratio and assumed financings, pre-transaction Redx holders are expected to own about 46.17% of the combined company, pre-transaction Skye holders about 5.38%, and investors in the concurrent and Series A financings about 48.45%, on a fully diluted basis, subject to net cash and other adjustments. Aggregate gross proceeds of roughly $125 million from a $67.9 million concurrent private financing, a $36.0 million Redx Series A round and related structures, plus an equity line facility of up to $22.0 million, are expected to fund operations into 2029, including a planned Phase 2 trial of lead asset RXC008 with topline data expected in the second half of 2028.
Skye will implement a 1‑for‑8 reverse stock split, reducing outstanding common shares from 35,421,413 to about 4,427,676 to support compliance with Nasdaq’s minimum bid price rule. Pre-transaction Skye stockholders will receive one contingent value right per share, giving them 90% of net cash proceeds, if any, from future monetization of nimacimab and related intellectual property over a defined period. Certain Redx holders will receive similar CVRs tied to Redx legacy assets.
Skye Bioscience, Inc. is moving its common stock listing from the Nasdaq Global Market to the Nasdaq Capital Market after falling out of compliance with the Global Market’s $10,000,000 minimum stockholders’ equity requirement. The company reported stockholders’ equity of $9,011,804 as of March 31, 2026.
Nasdaq approved the transfer effective with the open of business on June 23, 2026, and the trading symbol “SKYE” will remain unchanged. Separately, Skye previously received notice that its shares traded below the $1.00 minimum bid price for 30 consecutive business days, triggering a 180-day compliance period ending September 14, 2026. The company plans to monitor its share price and consider options to regain compliance but notes there is no assurance it will succeed.
Skye Bioscience, Inc. amended its charter to increase the number of authorized common shares from 100,000,000 to 300,000,000. This change does not affect the 35,126,884 common shares that were outstanding and entitled to vote as of April 2, 2026, but expands the shares the company may issue in the future.
The amendment was unanimously approved by the board and then approved by stockholders at the 2026 annual meeting, where a quorum of 23,529,424 shares, or 66.98% of those entitled to vote, was present. Stockholders also elected six directors, ratified CBIZ CPAs P.C. as auditor for 2026, and approved executive compensation on an advisory basis.
Skye Bioscience reported that Nasdaq has notified the company it no longer meets the Nasdaq Global Market stockholders’ equity requirement. Based on its Form 10-Q for the quarter ended March 31, 2026, stockholders’ equity was $9,011,804, below the $10,000,000 minimum under Listing Rule 5450(b)(1)(A).
The notice does not immediately affect trading, and the stock continues on the Nasdaq Global Market under the symbol SKYE. Skye has 45 days, until June 29, 2026, to submit a plan to regain compliance, with a potential extension of up to 180 days, to November 9, 2026, if Nasdaq accepts its plan. Failure to regain compliance could ultimately lead to delisting after any appeal process.
Skye Bioscience, Inc. filed an amended current report to correct a clerical error in an earlier disclosure about stock options. The company now states that the total number of shares of common stock underlying all repriced options is 2,458,158 shares. No other aspects of the prior report were changed.
Skye Bioscience, Inc. approved a broad stock option repricing and appointed a new chief financial officer. Effective March 31, 2026, all eligible employee stock options granted before December 31, 2025 under the company’s incentive plans had their exercise prices reset to $0.6150 per share, matching the common stock’s closing price that day. This affects 2,420,978 shares in total, including options for the CEO and COO, and is intended to retain and motivate employees without issuing additional equity or cash compensation.
On the same date, the board named John P. Sharp as Chief Financial Officer and principal financial and accounting officer. His services are provided through a Master Services Agreement with Lohman & Associates, under which the company pays $25,600 per month for up to 64 hours of CFO and related advisory services.
Skye Bioscience, Inc. received a Nasdaq deficiency letter on March 17, 2026 because its common stock’s closing bid price has stayed below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1) for The Nasdaq Global Market.
The stock continues trading under the “SKYE” symbol, and Skye has 180 calendar days, until September 14, 2026, to regain compliance, including the option to complete any reverse stock split at least ten business days before that date. If the bid price closes at or above $1.00 for at least 10 consecutive business days before that deadline, Nasdaq staff will confirm compliance. Skye may qualify for a second 180-day period on The Nasdaq Capital Market if it meets other listing standards and commits to curing the deficiency, but there is no assurance it will regain or maintain compliance.
Skye Bioscience reported fourth quarter and full-year 2025 results and detailed progress in its obesity program for nimacimab. In a Phase 2a trial, nimacimab plus semaglutide delivered 22.3% weight loss at 52 weeks and an approximately 3% incremental benefit at 26 weeks versus semaglutide alone, with a placebo-like safety profile and no drug-related neuropsychiatric events. Off-treatment, the combination cohort regained 17.8% of lost weight over 13 weeks versus 37.3% for semaglutide alone, with more favorable body composition changes. Skye has initiated a CBeyond Expansion Study testing 400 mg and 600 mg IV nimacimab and expects topline data in Q4 2026. Cash, cash equivalents and short-term investments totaled $25.7 million as of December 31, 2025, and the company expects this to fund operations and key clinical milestones through Q4 2026, excluding Phase 2b trial and related manufacturing costs. Full-year 2025 R&D expenses were $42.4 million and G&A expenses were $15.8 million, leading to a net loss of $55.9 million compared with $26.6 million in 2024.
Skye Bioscience announced that Chief Financial Officer Kaitlyn Arsenault will step down effective February 20, 2026 to pursue new professional opportunities and will continue as an advisor. Under a Separation and Release Agreement, she will receive a $450,000 cash severance, an additional $45,000 toward her 2026 annual bonus, reimbursement of up to $30,000 in legal fees, and a lump-sum payment of $41,172.48 equal to 12 months of COBRA premiums.
Certain outstanding equity awards will continue to vest during her advisory term, and unvested awards will fully vest if a Change in Control occurs within a year and before the advisory role ends. Vested stock options will remain exercisable until the later of February 20, 2027 or 90 days after the advisory term ends. The company states her departure is not due to any disagreement on financial reporting or company practices. In connection with this change, the Board appointed CEO Punit Dhillon as principal accounting officer, with his existing compensation and roles otherwise unchanged.
Skye Bioscience reported interim results from the combination cohort of its Phase 2a extension study of nimacimab for obesity. Nineteen participants who completed 26 weeks entered a further 26-week blinded extension, remaining on either nimacimab plus semaglutide or placebo plus semaglutide.
In the nimacimab plus semaglutide arm, mean weight loss was 14.4% at 26 weeks; seven completers lost an additional 7.9% over the extension, for 22.3% mean loss at 52 weeks. In the placebo plus semaglutide arm, mean weight loss was 13.9% at 26 weeks; seven completers lost an additional 5.8%, for 19.7% mean loss at 52 weeks. The combination remained safe and well tolerated, with no serious adverse events or adverse events of special interest reported.
The company expects full topline Phase 2a extension data, including nimacimab monotherapy and a 13-week off-therapy follow-up, in Q3 2026. It currently expects its capital to fund operations and key clinical milestones into the fourth quarter of 2026, excluding anticipated clinical and manufacturing costs for a proposed higher-dose Phase 2b trial.
Skye Bioscience furnished an update on its business and reported financial results for the period ended September 30, 2025 via a press release attached to a Form 8-K.
The company submitted the press release as Exhibit 99.1 under Item 2.02. Consistent with General Instruction B.2, this information is furnished and not deemed filed under the Exchange Act.
Skye Bioscience, Inc. (SKYE) announced it will host a conference call and live webcast to discuss a material event on October 6, 2025 at 8:00 a.m. ET. The filing states that the information under Item 7.01, including Exhibit 99.1, is being furnished and expressly notes it is not being "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other SEC filings except by specific reference. No financial results, tables, transactions, or additional details are included in the disclosed text.